A program cochair said the agenda was designed to get attendees "out of their comfort zone." The Amercian Association for ...

Endevica Bio, a privately held company developing first-in-class peptide drug candidates, announced today the dose administration for the first patient in a Phase 2 trial for its experimental drug ...

The College of Nurses of Ontario (CNO) welcomes the Ontario government's new bill to promote labour mobility in Canada, so we can continue to enable more nurses to provide safe ...

Stroke is the fourth leading cause of death among Hispanic men and the third leading cause for Hispanic women in the United States. Yet, according to CDC reports, only 58% of Hispanic adults can ...

As we mark Esophageal Cancer Awareness Month, Roswell Park Comprehensive Cancer Center highlights a recent study documenting "textbook" superior outcomes for 90% of 150 consecutive robot-assisted ...

A phase 1/2 trial (NCT06065462) is currently underway to evaluate the safety and efficacy of PP2A inhibition with LB-100 plus dostarlimab-gxly (Jemperli) in recurrent ovarian clear cell carcinoma. 3 ...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe ...

In oncology, while PARP inhibitors remain relatively static, Jemperli shows promising growth, particularly in endometrial cancer, where it splits the market evenly with Merck’s pembrolizumab.

We recently compiled a list of the 12 Best ADR Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other best ADR ...

Association Between Human Epidermal Growth Factor Receptor 2-Low Status and Time to Development of Brain Metastases Among Patients With Breast Cancer: A Retrospective Cohort Study A nationwide ...

PASADENA, Calif, March 27, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new ...

In oncology, while PARP inhibitors remain relatively static, Jemperli shows promising growth, particularly in endometrial cancer, where it splits the market evenly with Merck’s pembrolizumab.